Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271056 | 1.00 | MEN1 (0.43) | MEN1KMT2AGAAMAOAMAOB | |
| SCHEMBL15271475 | 0.98 | MEN1 (0.44) | MEN1KMT2AGAAMAOAMAOB | |
| SCHEMBL15271555 | 0.94 | MEN1 (0.44) | MEN1KMT2AGAAMAOAMAOB | |
| SCHEMBL2419909 | 0.90 | MEN1 (0.46) | MEN1KMT2AGAAALDH1A1HSD17B10 | |
| SCHEMBL30548748 | 0.85 | MAOA (0.44) | MEN1KMT2AGAAMAOAMAOB | |
| SCHEMBL20495594 | 0.85 | MAOA (0.44) | MEN1KMT2AGAAMAOAMAOB | |
| SCHEMBL24483663 | 0.81 | MEN1 (0.44) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL15888653 | 0.81 | HTR2C (0.50) | MEN1KMT2AGAASIGMAR1CYP2D6 | |
| SCHEMBL30958574 | 0.79 | ALDH1A1 (0.47) | MAOAMAOBALDH1A1HPGDMAPT | |
| SCHEMBL15270962 | 0.78 | GAA (0.40) | MEN1KMT2AGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650456-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| CN-104220466-B | For the method preparing polydiene | 株式会社普利司通 | 2016-09-21 | — | — | CN | disclosed |
| EP-2825574-B1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150031845-A1 | Process For Producing Polydienes | BRIDGESTONE CORPORATION (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2825574-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| CN-104220466-A | Process for producing polydienes | BRIDGESTSONE CORP | 2014-12-17 | — | — | CN | disclosed |
| WO-2013138270-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTSONE CORPORATION (JP) | 2013-09-19 | — | — | WO | disclosed |
| EP-2275413-B1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | NQO2, QTRT1, QTRT2 | MEN1 2988/4885KMT2A 1241/4885GAA 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.